Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin

Blood Reviews

Volumn 14, Issue 1, 2000, Pages 14-30

  Rhoades, C J ^a   Williams, M A ^a   Kelsey, S M ^a   Newland, A C ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BACTERIAL TOXIN; FC RECEPTOR; IMMUNOGLOBULIN; SUPERANTIGEN;

DRUG MECHANISM; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK;

EID: 0034095055     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.1999.0121     Document Type: Review

References (113)

1. Cohn E. J., Luetscher J. A. Jr, Oncley J. L., Armstrong S. H. Jr, Davis B. D. Preparations and properties of serum and plasma proteins. III. Size and charge of proteins separating upon equilibration across membranes with ethanol-water mixtures of controlled pH, ionic strength and temperature. J Am Chem Soc. 62:1940;3396-3400.
2. Cohn E. J., Strong L. E., Hughes W. L. Jr. Preparations and properties of serum and plasma proteins. I. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 68:1946;459-475.
3. Janeway C. A., Rosen F. S. The gammaglobulins IV. Therapeutic uses of gammaglobulin. New Eng J Med. 275:1966;826-831.
4. Barandun S., Kistler P., Jeunet F., Isliker H. Intravenous administration of human gammaglobulin. Vox Sang. 7:1962;157-174.
5. Barandun, S. Riva, G. Spengler, G. A. Immunologic deficiency: diagnosis, forms and current treatment. D. Bergsma, Immunological Deficiency Diseases in Man. Birth Defects Original Article Series, VI, March of Dimes, White Plains, New York, 40, 49.
6. Kaveri S. V., Dietrich G., Hurez V., Kazatchkine D. Intravenous immunoglobulin (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol. 86:1991;192-198.
7. Leung D. Y. M. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralisation by intravenous immunoglobulin. Clin Exp Immunol. 104 (suppl 1):1996;49-54.
8. Newland A. C., Treleaven J. G. High dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet. 1983;84-87.
9. Imbach P., Barandun S., d'Apuzzo V. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1228-1231.
10. Dalakas M. C. Clinical benefits and immunopathological correlates of Intravenous Immune Globulin in the treatment of inflammatory myopathies. Clin Exp Immunol. 104(suppl 1):1996;55-60.
11. Gelfand E. W., Landwehr L. P., Esterl B., and Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol. 104(suppl 1):1996;61-66.
12. Olopoenia L., Young M., White D., Barnes S., Rahbar F., Fomufod A. Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection. J Natl Med Assoc. 89(8):1997;543-547.
13. Mouthon L., Kaveri S. V., Spalter S. H., Lacroix-Desmazes S., Lefranc C., Desai R., Kazatchkine M. D. Mechanisms of action of intravenous immune globulin in immune mediated diseases. Clin Exp Immunol. 104(suppl 1):1996;3-9.
14. Dwyer J. M. Manipulating the Immune system with Immune Globulin. New Eng J Med. 326:1992;107-114.
15. Basta M., Langolis P. F., Marques M., Frank M. M., Fries L. F. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood. 74(1):1989;326-333.
16. Newland A. C. The use and mechanisms of action of intravenous immunoglobulin: an update. Br J Haemat. 72:1989;301-305.
17. Kimberly R. P., Salmon J. E., Bussel J. B., Crow M. K., Hilgartner M. W. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol. 132:1984;745-750.
18. Intravenous Immunoglobulin Therapy. Clinical benefits and future Prospects. Summary of discussions held during an international roundtable. Barcelona, June 1994. M. D. Kazatchkine, Patherton Publishing.
19. Ballow M. Mechanisms of action of intravenous immune serum globulin therapy. Paediatric Infec Dis J. 13:1994;806-811.
20. Basta M., Kirshbom P., Frank M. M., Fries L. F. Mechanisms of therapeutic effect of high-dose intravenous immunoglobulin attenuation of acute, complement-dependant immune damage in a guinea pig model. J Clin Invest. 4:1989;1974-1981.
21. Toungouz M., Denys C. H., De Groote D., Dupont E. In vitro inhibition of tumour necrosis factor -α and interleukin - 6 production by intravenous immunoglobulins. Br J Haemat. 89:1995;698-703.
22. Darville T., Milligan L. B., Laffoon K. K. Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production. Infect Imm. 65:1997;366-372.
23. Gelfand E. W., Landwehr L. P., Esterl B., Mazer B. Intravenous Immune Globulin: an alternative therapy in steroid-dependent allergic disease. Clin Exp Immunol. 104:1996;61-66.
24. Svenson M., Hansen M. B., Ross C. Antibody to granulocyte-macrophage colony-stimulaing factor is a dominant anti-cytokine activity in human IgG preparations. Blood. 91:1998;2054-2061.
25. Yu Z., Lennon V. A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. New Eng J Med. 340(3):1999;227-228.
26. Lynn W. A., Cohen J. Management of septic shock. J Infect. 30:1995;207-212.
27. Williams M. A., Rhoades C. J., Newland A. C., Kelsey S. M. The potential for monocyte mediated immunotherapy during infection and malignancy. Part 2: In vivo activation by exogenous cytokines and clinical applications. Leuk Lymphoma. 34(3-4):1999;207-230.
28. Williams M. A., Newland A. C., Kelsey S. M. The immunotherapeutic potential of the monocyte. The Cancer Journal. 11(3):1998;111-126.
29. Williams M. A., Newland A. C., Kelsey S. M. The potential for monocyte mediated immunotherapy during infection and malignancy. Part 1: Apoptosis induction and cytotoxic mechanisms. Leuk Lymphoma. 34(1-2):1999;1-23.
30. Van de Winkel J. G. J., Capel P. J. A. Human IgG Fc Receptor Heterogeneity: Molecular Aspects and Clinical Implications. Immunol Today. 14(5):1993;215-221.
31. Fanger M. W., Erbe D. V. Fc receptors in cancer and infectious diseases. Immunol Res. 11:1992;203-216.
32. Thrasher A. J., Keep N. H., Wientses F., Segal A. W. Chronic granulomatous disease. Biochim Biophys Acta. 1227:1994;1-24.
33. Isobe M., Suzuki J., Yamazaki S. Regulation by differential development of Th1 and Th2 Cells in peripheral tolerance to cardiac allograft induced by blocking ICAM-1/LFA-1 adhesion. Circulation. 96(7):1997;2247-2253.
34. Nagumo H., Agematsu K. Synergisitic augmentative effect of interleukin-10 and CD27/CD70 interactions on B-cell immunoglobulin synthesis. Immunol. 94(3):1998;388-394.
35. Urashima M., Chauhan D., Hatziyanni M. CD40 ligand triggers interleukin-6 mediated B cell differentiation. Leuk Res. 20(6):1996;507-515.
36. Uejima Y., Takahashi K., Komoriya K., Kurozumi S., Ochs H. D. Effect of interleukin-10 on anti-CD40- and interleukin-4-induced immunoglobulin E production by human lymphocytes. Int Arch Allergy Immunol. 110(3):1996;225-232.
37. Burdin N., Van Kooten C., Galibert L. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol. 154(6):1995;2533-2544.
38. Ueno Y., Takano N., Kanegane H. The acute phase nature of interleukin 6 studied in kawasaki disease and other febrile illness. Clin Exp Immunol. 76:1989;337-342.
39. Bundschuh D. S., Barsig J., Hartung T., Randow F., Döcke W., Volk H., Wendel A. Granulocyte-macrophage colony-stimulating factor and IFN-γ restore the systemic TNF-α response to endotoxin in lipopolysaccharide-desensitized mice. J Immunol. 158:1997;2862-2871.
40. Williams M. A., Kouroumoussis I., Syndercombe-Court D., Hendry L., Newland A. C., Kelsey S. M. Administration of granulocyte-macrophage colony stimulating factor (rHuGM-CSF) after chemotherapy regulates the expression and secretion of monocyte TNF and TNF receptors p55 and p75. Blood. 86:1995;4234-4242.
41. Williams M. A., Newland A. C., Kelsey S. M. Monocyte mediated killing of human leukaemia is enhanced by administration of granulocyte-macrophage colony stimulating factor following chemotherapy. Br J Haemat. 90:1995;31-40.
42. Morrison D. C., Cochrane C. G. Direct evidence for Hageman Factor (Factor XII) activation by bacterial lipopolysaccharides. J Exp Med. 140:1974;797-810.
43. Yao J., Mackman N., Edington T. S., Fan S. Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells. J Biol Chem. 272(28):1997;17795-17801.
44. Robak E., Sysa-Jedrzejewska A., Dziankowska B., Torzecka D., Chojnowski K., Robak T. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythramatosis activity. Arch Immunol Ther Exp. 46(6):1998;375-380.
45. Manufacturers data sheet compendium.
46. Aukrust P., Frøland S. S., Liabakk N., Müller F., Nordøy I., Haug C., Espevik T. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 84(7):1994;2136-2143.
47. Anderson J., Skansén-Saphir U., Sparrelid E., Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol. 104(suppl 1):1996;10-20.
48. Kimberly R. P., Ralph P. Endocytosis by the mononuclear phagocyte system and autoimmune diseases. Am J Med. 74:1983;481-493.
49. 2fragments. Clin Exp Immunol. 111:1998;583-587.
50. Achiron A., Barak Y., Goren M. Intravenous immunoglobulin in multiple sclerosis: clinical and neuroradiological results and implications for possible mechanisms of action. Clin Exp Immunol. 104(suppl 1):1996;67-70.
51. Andersson U. G., Björk L., Skansén-Saphir U., Andersson J. P. Down-regulation of cytokine production and interleukin -2 receptor expression by pooled human IgG. Immunol. 79:1993;211-216.
52. 2+dependant signal transduction through Fcγ receptors in B lymphocytes. Scand J Immunol. 40:1994;37-42.
53. Newburger J. W., Takahashi M., Burns J. C. The treatment of kawasaki syndrome with intravenous gamma globulin. New Eng J Med. 315(6):1986;341-347.
54. Newland A. C., Macey M. G. Immune thrombocytopenia and Fc receptor mediated phagocyte function. Ann Hematol. 1994;69-67.
55. Aukrust P., Müller F., Nordøy I., Haug C. J., Frøland S. S. Modulation of lymphocyte and monocyte activity after intravenous immunoglobulin administration in vivo. Clin Exp Immunol. 107:1997;50-56.
56. Toungouz M., Denys C., Dupont E. Blockade of proliferation and tumor necrosis factor -α production occurring during mixed lymphocyte reaction by interferon-γ-specific natural antibodies contained in intravenous immunoglobulins. Transplantation. 62(9):1996;1292-1296.
57. Rigal D., Vermot-Desroches C., Heitz S., Bernaud J., Alfonsi F., Monier J. C. Effects of intravenous immunoglobulins (IVIg) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules. Clin Immunol Immunopath. 71(3):1994;309-314.
58. Bagdasarian A., Tonetta S., Harel W., Mamidi R., Uemura Y. IVIg adverse reactions: potential role of cytokine and vasoactive substances. Vox Sang. 74:1998;78-82.
59. Anderson J. P., Andersson U. G. Human intravenous immunoglobulin modulates monokine production in vitro. Immunol. 71:1990;372-376.
60. Skansén-Saphir U., Andersson J., Björk L., Andersson U. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down regulated by pooled human IgG. Eur J Immunol. 24:1994;916-922.
61. Ruis de Sousa V., Carreno M., Kaveri S. V. Selective induction of IL-1ra and IL-8 in human monocytes by normal polyspecific IG (IVIg). Eur J Immunol. 25:1995;1267-1273.
62. Huber C., Batchelor J. R., Fuchs D. Immune response associated production of neopterin. J Exp Med. 160:1984;310-316.
63. Ling Z., Yeoh E., Webb B. T., Farrell K., Douchette J., Matheson D. S. Intravenous Immunoglobulin Induces Interferon-γ and Interleukin-6 in vivo. J Clin Immunol. 13(5):1993;302-309.
64. Shimozato T., Iwata M., Tamura N. Suppression of TNF-α production by human immunoglobulin preparations for intravenous use. Infect Imm. 58:1990;1384-1390.
65. Hellstrand K., Kjellson B., Hermodsson S. Monocyte-induced down-modulation of CD16 and CD56 antigens on human natural killer cells and its regulation by histamine H2 receptors. Cell Immunol. 138:1991;44-54.
66. Toyoda M., Zhang X., Petrosian A., Galera O. A., Wang S., Jordan S. C. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol. 14(3):1994;178-189.
67. Aukrust P., Hestdal K., Lien E. Effects by intravenous immunoglobulin in vivo on abnormally increased TNF-α activity in human immunodeficiency virus type 1 infection. J Infect Dis. 176:1997;913-923.
68. Shimozato T., Iwata M., Kawada H., Tamura N. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production. Immunol. 72:1991;497-501.
69. Katakami Y., Nakao Y., Koizumi Y., Katakami N., Ocawa R., Fujita T. Regulation of tumor necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMP. Immunol. 64:1988;719.
70. Kundsen P. J., Dinarello C. A., Strom T. B. Prostaglandins postotranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol. 137:1986;3189.
71. Basta M. Modulation of complement mediated immune damage by intravenous immunoglobulin. Clin Exp Immunol. 104(suppl. 1):1996;21-25.
72. Wagner E., Platt J. L., Frank M. M. High dose intravenous immunoglobulin does not affect complement bacteria interactions. J Immunol. 160:1998;1936-1943.
73. 2mediated anti-complement activity. Clin Exp Immunol. 110:1997;122-126.
74. Shintani N., Nakajima T., Nakakubo H. Intravenous Immunoglobulin treatment of experimental colitis induced by dextran sulfate sodium in rats. Clin Exp Immunol. 108:1997;340-345.
75. Basta M., Fries L. F., Frank M. M. High doses of intravenous Ig inhibits in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood. 77:1991;376-380.
76. Jones E. A., Waldmann T. A. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest. 51:1972;2916-2927.
77. Junghans R. P., Anderson C. L. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA. 93:1996;5512-5516.
78. Abdou M. I., Wall H., Lindsley H. B., Hasley J. F., Sushi T. Network theory in autoimmunity: in vitro suppression of serum anti DNA antibody binding to DNA by anti-idiotype antibody in systemic lupus erythematosus. J Clin Invest. 67:1981;1297-1304.
79. Sultan Y., Maisonneuve P., Kazatchkine M. D., Nydegger U. E. Anti-idiotype suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 2:1984;765-768.
80. Abbas, A. K. Lichtman, A. H. Pober, J. S. Cellular and Molecular Immunology 2nd Edition, W.B. Saunders Company, Philadelphia. 322, 323.
81. Van Scheik I. N., Lunduist I., Vermeulen M., Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol. 12:1992;325-334.
82. Reeves, G. Todd, I. Lecture Notes on Immunology, 157, Blackwell Science Ltd, Oxford, UK.
83. Bussel J., Pahwa S., Porges A. Correlation of in vitro antibody synthesis with the outcome of intravenous gamma-globulin treatment of chronic idiopathic thrombocytopenic purpura. J Clin Immunol. 6:1986;50-56.
84. MacMicking J. D., Nathan C., Hom G. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell. 81:1995;641-650.
85. Moncada S., Higgs A. Mechanisms of disease: the L-arginine-nitric oxide pathway. New Engl J Med. 329:1993;2002-2012.
86. Weinberg J. B., Misukonis M. A., Shami P. J. Human mononuclear phagocyte inducible nitric oxide synthasse (iNOS): Analysis of iNOS mRNA, iNOS protein, Biopterin and nitric oxide production by blood monocytes and peritoneal macrophages. Blood. 86:1995;1184-1195.
87. Hill J. R., Corbett J. A., Kwon G., Marshall C. A., McDaniel M. L. Nitric oxide regulates interleukin 1 bioactivity released from murine macrophages. J Biol Chem. 271:1996;22672-22678.
88. Williams M. A., Rhoades C. J., Lewis A., Newland A. C., Kelsey S. M. Intravenous Immunoglobulin blocks nitric oxide synthesis and activation induced apoptosis in THP-1 macrophage cells. Haematologica. 84:1999;254.
89. Viard I., Wehrli P., Bullani R. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 282:1998;490-493.
90. Prasad N. K. A., Papoff G. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 161:1998;3781-3790.
91. Ahsan N. Intravenous immunoglobulin induced - nephropathy: a complication of IVIg therapy. J Nephrol. 11:1998;157-161.
92. Buckley R. H., Schiff R. I. New. The use of intravenous immune globulin in Immunodeficiency diseases. Engl J Med. 325(2):1991;110-117.
93. Kaveri S. V., Dietrich G., Hurez V., Kazatchkine M. D. Intravenous immunoglobulin in the treatment of autoimmune diseases. Clin Exp Immunol. 86:1991;192-198.
94. Jolles S., Hughes J., Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol. 134:1998;80-86.
95. Dickler H. B., Gelfand E. W. Current perspectives on the use of IVIg. Adv Intern Med. 41:1996;641-680.
96. Werdan K., Pilz G. Supplemental immune globulins in sepsis: a critical appraisal. Clin Exp Immunol. 104(suppl 1.):1996;83-90.
97. Anderson M. R., Blumer J. L. New advances in the therapy for sepsis in children. Pediatr Clin North Am. 44:1997;179-205.
98. Haque K. N., Remo C., Bahakim H. Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin Exp Immunol. 101:1995;328-333.
99. Christensen R. D., Broun M. S., Hall D. C., Lassiter H. A., Hill H. R. Effect of neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early onset sepsis. J Pediatr. 118:1991;606-614.
100. Barry W., Hudgins L., Donta S. T., Pesanti E. L. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA. 267:1992;3315-3316.
101. Pap T., Reinhold D., Kekow J. Effects of intravenous immunoglobulins on disease activity and cytokine plasma levels in rheumatoid arthritis. Scand J Rheumatol. 27:1998;157-159.
102. Kanik K. S., Yarboro C. H., Naparstek Y., Wilder R. L. Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis and Rheumatism. 39(6):1996;1027-1029.
103. Tumiati B., Casoli P., Veneziani M., Rinaldi G. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis and Rheumatism. 335(10):1992;1126-1133.
104. Bagge E., Geijer M., Tarkowski A. Intra-articular administration of polyclonal immunoglobulin G in rheumatoid arthritis. A double-blind, placebo-controlled pilot study. Scand J Rheumatol. 25:1996;174-176.
105. Prieur A. Intravenous immunoglobulins in Still's disease: still controversial, still unproven. J Rheumatol. 23(5):1996;797-799.
106. Uziel Y., Laxer R. M., Schneider R., Silverman E. D. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a follow-up study. J Rheumatol. 23:1996;910-918.
107. Tumiati B., Casoli P., Veneziani M., Rinaldi G. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis and Rheumatism. 335(10):1992;1126-1133.
108. Cotton P. Infant AIDS prevention study finally gets going. JAMA. 270(15):1993;1785.
109. Lambert J. S., Mofenson L. M., Fletcher C. V. Safety and pharmokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocal 185 Pharmacokinetic Study Group. J Infect Dis. 175(2):1997;283-291.
110. Cummins L. M., Weinhoid K. J., Matthews T. J. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus seropositive donors. Blood. 77(5):1991;1111-1117.
111. Fletcher C. V., Goodroad B. K., Cummins L. M., Henry K., Balfour H. R. Jr, Rhame F. S. Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. Antimicrob Agents Chemother. 41(7):1997;1571-1574.
112. Tankersley D. L. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune disease. Immunol Rev. 139:1994;159-172.
113. Alving B. M., Tankersley D. L., Mason B. L., Rossi F., Aronson D. L., Finlayson J. S. Contact activated factors: contaminants of immunoglobulin preparations with coagulant and vasoactive properties. J Lab Clin Med. 96:1980;334-346.